Market regulator SEBI sets sights on the booming PE, VC funding of startups. From valuation methodology to the valuation ‘manager’ SEBI is seeking answers from the hottest ecosystem that is now facing a funding winter. Host Arijit Barman talks to Sugata Ghosh, Associate Editor The Economic Times, Pratibha Jain, Head of Strategy and Group General Counsel at Everstone Group and Tushar Aggarwal, Founder and CEO at Stashfin.
Credits: WION, MoneyControl, NDTV, CNBC-TV18, Business Today, ET NOW

Market regulator SEBI sets sights on the booming PE, VC funding of startups. From valuation methodology to the valuation ‘manager’ SEBI is seeking answers from the hottest ecosystem that is now facing a funding winter. Host Arijit Barman talks to Sugata Ghosh, Associate Editor The Economic Times, Pratibha Jain, Head of Strategy and Group General Counsel at Everstone Group and Tushar Aggarwal, Founder and CEO at Stashfin. Credits: WION, MoneyControl, NDTV, CNBC-TV18, Business Today, ET NOW

To make sense of the week’s hottest stories in business, economy, politics and markets, journalists from the Economic Times chat with reporters and industry leaders in this thrice-weekly (Tuesday, Thursday, Friday) podcast.

The Morning Brief

SEBI's Brush with Upstart Valuations

Work Rewritten by AI

LinkedIn as AI Engine

AI Skills Across Jobs

Redesigning Roles and Mentorship

Skills Frameworks and Verified Skills

Closing the Skills Gap

AI Tools and Doer to Director

Bias Transparency and Control

Final Takeaways 

A billion professionals. Eighteen years of data. And a skills gap that's widening as AI tools multiply. Mohak Shroff has watched LinkedIn evolve from a professional network into what he calls, at its core, an AI matching engine. That vantage point gives Shroff, SVP Engineering at Linkedin, a clear read on what's actually happening inside organisations right now. Not the boardroom narrative, but the messy reality of workers who don't know which skills to build, recruiters who can't find candidates despite better tooling, and companies confusing access to AI with genuine AI readiness.

Listen in

A billion professionals. Eighteen years of data. And a skills gap that's widening as AI tools multiply. Mohak Shroff has watched LinkedIn evolve from a professional network into what he calls, at its core, an AI matching engine. That vantage point gives Shroff, SVP Engineering at Linkedin, a clear read on what's actually happening inside organisations right now. Not the boardroom narrative, but the messy reality of workers who don't know which skills to build, recruiters who can't find candidates despite better tooling, and companies confusing access to AI with genuine AI readiness.
Listen in

From Doer to Director: The LinkedIn Playbook for the AI Age

Generic AI flood: excited chaos, or just noise

GLP-1s: The New Standard for Metabolic Care?

India's GLP-1 Race: Rules, Reach & Reality

Post-March 21st: Who Wins the GLP-1 Market?

Stand Out or Fade Out in the GLP-1 Race

Big or Small: Who Wins the GLP-1 Script?

Will Patients Stick With GLP-1s This Time?

GLP-1 Buzz: Awareness or a Recipe for Misuse

GLP-1 Safeguards: Are Global Checks Enough?

Semaglutide Goes Global: Even Africa Is Next?

Pills or Shots: How Will Semaglutide Be Taken?

Will Small Molecules Challenge the GLP-1 Era?

Dos & Don'ts: For Companies and Patients Both

Conclusion

Credits

India's semaglutide moment has arrived. As Novo Nordisk's patent expires on March 20th, over fifty generic brands are poised to flood the market potentially slashing monthly costs from ₹10,000 to ₹3,500. But this is no ordinary generic wave. Semaglutide is a complex peptide, cold chains are unforgiving, and patient adherence remains fragile. Host and ET’s pharma editor Vikas Dandekar talks to Sheetal Sapale, Vice President, Pharmarack, Dr. Rajiv Kovil, Diabetologist, Saurabh Agarwal, Director at HAB Pharmaceuticals and Research, Dr. Saurabh Jain, Vice President - Global Delivery Centers, Indegene and Vijay Charlu, President of Domestic Business, Corona Remedies to dissect who survives the shakeout, what it means for a slew of weight loss drugs in India, whether it will revolutionise metabolic treatment and whether India is truly ready for its statin moment.

You can follow Vikas Dandekar on his social media: X and Linkedin and read her Newspaper Articles.

Check out other interesting episodes like: How Will a Volatile ₹ Impact You in 2026?, How Quick Commerce is Triggering a Health Crisis for Gen Z, India’s Labour Law Reboot, Viral to Valuation: Building Women’s Cricket as a Brand and much more.

Catch the latest episode of ‘The Morning Brief’ on The Economic Times Online, Spotify, Apple Podcasts, JioSaavn, Amazon Music and Youtube.

India's semaglutide moment has arrived. As Novo Nordisk's patent expires on March 20th, over fifty generic brands are poised to flood the market potentially slashing monthly costs from ₹10,000 to ₹3,500. But this is no ordinary generic wave. Semaglutide is a complex peptide, cold chains are unforgiving, and patient adherence remains fragile. Host and ET&rsquo;s pharma editor Vikas Dandekar talks to Sheetal Sapale, Vice President, Pharmarack, Dr. Rajiv Kovil, Diabetologist, Saurabh Agarwal, Director at HAB Pharmaceuticals and Research, Dr. Saurabh Jain, Vice President - Global Delivery Centers, Indegene and Vijay Charlu, President of Domestic Business, Corona Remedies to dissect who survives the shakeout, what it means for a slew of weight loss drugs in India, whether it will revolutionise metabolic treatment and whether India is truly ready for its statin moment. You can follow Vikas Dandekar on his social media: <a href="https://twitter.com/VikasReports">X</a> and <a href="https://www.linkedin.com/in/vikas-dandekar-2a0a619">Linkedin</a> and read her <a href="https://economictimes.indiatimes.com/etreporter/author-vikas-dandekar-479242213.cms?from=mdr">Newspaper Articles</a>. Check out other interesting episodes like: <a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000742733036">How Will a Volatile ₹ Impact You in 2026?</a>, <a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000740924439">How Quick Commerce is Triggering a Health Crisis for Gen Z</a>, <a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000738734300">India&rsquo;s Labour Law Reboot</a>, <a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000738205536">Viral to Valuation: Building Women&rsquo;s Cricket as a Brand</a> and <a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777">much more</a>. Catch the latest episode of &lsquo;The Morning Brief&rsquo; on <a href="https://economictimes.indiatimes.com/podcast?from=mdr">The Economic Times Online</a>,<a href="https://open.spotify.com/show/6PL5kfPbwURBEu6fHCVTOL?si=26ec0fbfa7134fea"> Spotify</a>, <a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777">Apple Podcasts</a>, <a href="https://www.jiosaavn.com/shows/the-morning-brief/1/GNPiFQD2xpY_">JioSaavn</a>, <a href="https://music.amazon.in/podcasts/f378141f-9afb-495d-83da-9b08ec5047ac/the-morning-brief">Amazon Music</a> and <a href="https://www.youtube.com/@theetpodcasts">Youtube</a>.

Semaglutide Goes Generic: Big Pharma’s Moat Breaks

AI, Ethics & The Pentagon: Who Draws The Line?

Big Tech vs Governments: Who Controls AI?

Can You Trust AI Tools Made In America?

Why Businesses Are Questioning Their AI Tools

Politics Or Profits: Big Tech Must Choose

When AI Decides Who Lives And Who Dies

Anthropic refused the Pentagon unrestricted access to its Claude AI, and the fallout reshaped the tech-defense landscape overnight. OpenAI rushed in to fill the void, signing a classified deal that triggered internal resignations and a user exodus toward Claude. Host Himanshi Lohchab talks to Abishur Prakash, Geopolitical Strategist, to unpack the fierce power struggle between governments demanding unrestricted AI and companies defending their ethical red lines. They also examine sovereign AI, battlefield automation, and whether Big Tech can or should stay out of warfare. The age of AI geopolitics has arrived. 

Listen in.

You can follow Himanshi Lohchab on her social media: X and Linkedin

Check out other interesting episodes like: How Will a Volatile ₹ Impact You in 2026?, How Quick Commerce is Triggering a Health Crisis for Gen Z, India’s Labour Law Reboot, Viral to Valuation: Building Women’s Cricket as a Brand and much more.

Catch the latest episode of ‘The Morning Brief’ on The Economic Times Online, Spotify, Apple Podcasts, JioSaavn, Amazon Music and Youtube.

Anthropic refused the Pentagon unrestricted access to its Claude AI, and the fallout reshaped the tech-defense landscape overnight. OpenAI rushed in to fill the void, signing a classified deal that triggered internal resignations and a user exodus toward Claude. Host Himanshi Lohchab talks to Abishur Prakash, Geopolitical Strategist, to unpack the fierce power struggle between governments demanding unrestricted AI and companies defending their ethical red lines. They also examine sovereign AI, battlefield automation, and whether Big Tech can or should stay out of warfare. The age of AI geopolitics has arrived. Listen in. You can follow Himanshi Lohchab on her social media: <a href="https://x.com/HimanshiET">X</a> and <a href="https://www.linkedin.com/in/himanshi-lohchab-751804173/">Linkedin </a>Check out other interesting episodes like: <a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000742733036">How Will a Volatile ₹ Impact You in 2026?</a>, <a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000740924439">How Quick Commerce is Triggering a Health Crisis for Gen Z</a>, <a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000738734300">India&rsquo;s Labour Law Reboot</a>, <a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000738205536">Viral to Valuation: Building Women&rsquo;s Cricket as a Brand</a> and <a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777">much more</a>. Catch the latest episode of &lsquo;The Morning Brief&rsquo; on <a href="https://economictimes.indiatimes.com/podcast?from=mdr">The Economic Times Online</a>,<a href="https://open.spotify.com/show/6PL5kfPbwURBEu6fHCVTOL?si=26ec0fbfa7134fea"> Spotify</a>, <a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777">Apple Podcasts</a>, <a href="https://www.jiosaavn.com/shows/the-morning-brief/1/GNPiFQD2xpY_">JioSaavn</a>, <a href="https://music.amazon.in/podcasts/f378141f-9afb-495d-83da-9b08ec5047ac/the-morning-brief">Amazon Music</a> and <a href="https://www.youtube.com/@theetpodcasts">Youtube</a>.

SEBI's Brush with Upstart Valuations

In 1 playlist(s)

The Morning Brief

Social links

Follow podcast

Recent clips